Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 15/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.36 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.36 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799503 | 1.00 | HSD17B3 (0.49) | HSD17B3SMN1; SMN2P2RX4PTBP1P2RX1 | |
| SCHEMBL4797840 | 0.85 | HSD17B3 (0.48) | HSD17B3MAPTTSHRCACNA1B | |
| SCHEMBL4798520 | 0.85 | HSD17B3 (0.48) | HSD17B3P2RX4TSHR | |
| SCHEMBL4798515 | 0.85 | HSD17B3 (0.48) | HSD17B3P2RX4TSHR | |
| SCHEMBL4797859 | 0.85 | HSD17B3 (0.48) | HSD17B3MAPTTSHRCACNA1B | |
| SCHEMBL4225884 | 0.84 | HSD17B3 (0.47) | HSD17B3SMN1; SMN2P2RX4P2RX1P2RX3 | |
| SCHEMBL4225889 | 0.84 | HSD17B3 (0.47) | HSD17B3SMN1; SMN2P2RX4P2RX1P2RX3 | |
| SCHEMBL4798102 | 0.84 | HSD17B3 (0.47) | HSD17B3SMN1; SMN2P2RX4NPC1TP53 | |
| SCHEMBL4798094 | 0.84 | HSD17B3 (0.47) | HSD17B3SMN1; SMN2P2RX4NPC1TP53 | |
| SCHEMBL4800826 | 0.81 | HSD17B3 (0.45) | HSD17B3P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885SMN1; SMN2 4127/4885P2RX4 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.